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Abstract
Because both renal disease and immune activation predict progression to AIDS, we evaluated the
relationships between dipstick proteinuria ≥1+ [7% of 1012 subjects], CrCl <90mL/min [18% of
1071 subjects], and percentages of peripheral activated CD8 cells (CD8+CD38+HLA-DR+) in
antiretroviral-naïve, HIV-infected subjects enrolled into AIDS Clinical Trials Group studies 384
and A5095. Proteinuria, but not CrCl, was associated with higher percentages of
CD8+CD38+HLA-DR+ cells [55% vs. 50%; P=0.01], with even more pronounced differences in
men and among Blacks and Hispanics. Proteinuria may be a surrogate measure of greater immune
activation in HIV-infected patients initiating antiretroviral therapy.
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Two U.S. based cohort studies of HIV-infected women have demonstrated that proteinuria
and renal function are independent predictors of both progression to AIDS [1] and overall
mortality [1,2], even when accounting for CD4 cell count, HIV-1 RNA level, history of
AIDS, and use of antiretroviral therapies. The mechanism by which these markers of kidney
disease are independently associated with poorer outcomes is unknown.
Corresponding Author: Dr. Samir K. Gupta, Division of Infectious Diseases, Indiana University School of Medicine, Wishard
Hospital, OPW-430, 1001 W. 10th Street, Indianapolis, IN, 46202, sgupta1@iupui.edu, phone: 317-630-6119, fax: 317-630-7522.
Conflicts of Interest: None for all authors.
This manuscript was presented in part at the 9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV,
Sydney, Australia, July 19–21, 2007.
NIH Public Access
Author Manuscript
J Infect Dis. Author manuscript; available in PMC 2010 April 22.
Published in final edited form as:













Increased levels of activated T cells, especially CD8 cells, are independently associated with
faster progression to AIDS and death [3]. Immune activation decreases with combination
antiretroviral therapy (cART) but generally do not return to levels found in HIV-uninfected
individuals [4], suggesting that even treated HIV infection is associated with chronic
activation of T cells.
The kidneys are known reservoirs for persistent HIV replication even when peripheral viral
load is suppressed with cART [5]. Kidneys in patients with HIV-associated nephropathy
have a dense tubulointerstitial inflammatory infiltrate, primarily composed of activated CD4
and CD8 cells, and the amount of the infiltrate appears to correlate with the degree of
clinical nephropathy [6]. It has been suggested that HIV-infected renal tubular epithelial
cells trigger upregulation of pro-inflammatory genes [7]. This pro-inflammatory renal
environment may stimulate increased immune activation in the kidneys which may
consequently lead to heightened systemic immune activation. Alternatively, patients with
increased systemic immune activation may be prone to having infiltration of activated T
cells into the kidneys, thereby leading to proteinuria and reduced renal function.
Therefore, we hypothesized that markers of renal disease, namely dipstick proteinuria and
reduced CrCl, are associated with higher levels of peripheral blood activated T cells in
antiretroviral-naïve HIV-infected subjects.
Subjects, materials, and methods
A cross-sectional analysis of pre-cART data from subjects participating in AIDS Clinical
Trials Group (ACTG) 384 [8] and A5095 [9] was performed. Urine dipstick, serum
creatinine, and advanced flow cytometry measurements were available prior to cART
initiation in U.S. participants in ACTG 384. Urine dipstick and serum creatinine, but not
advanced flow cytometry, were systematically collected prior to cART in A5095. A subset
of A5095 subjects who co-enrolled into A5001, the ACTG Longitudinal Linked
Randomized Trial [ALLRT], had advanced flow cytometry measured at randomization.
Eligibility criteria for ACTG 384 and A5095 were similar, including the requirement for
both studies that pre-cART serum creatinine be less than 1.5 times the upper limit of normal
at the local laboratory.
Proteinuria was defined by the presence of ≥1+ protein on dipstick. We defined reduced
renal function as an estimated CrCl (CrCl) <90mL/min as only 9 subjects had estimated
CrCl <60mL/min. We estimated CrCl using the Cockcroft-Gault formula [10] for these
analyses, instead of with glomerular filtration rate using the Modification of Diet in Renal
Disease formula, as CrCl may be more consistent in predicting HIV disease progression and
mortality in antiretroviral-naïve patients (Wools-Kaloustian K, et al.; Abstract 741, 16th
Conference on Retroviruses and Opportunistic Infections, 2009). T cell activation was
determined by the proportion of CD3+CD8+CD38+HLA-DR+ cells on advanced flow
cytometry using standardized methodology in ACTG approved laboratories [11].
Data are presented as medians (interquartile ranges, IQR). Between-group statistical
comparisons used either the Wilcoxon rank-sum or Fisher’s exact tests, as appropriate.
Logistic regression was used to investigate the association between immune activation and
≥1+ dipstick proteinuria or CrCL< 90, after adjusting for potential explanatory variables.
Linear correlations between CrCl and immune activation levels were also performed. P-
values below 0.05 were considered statistically significant.
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In the combined ACTG 384 and ACTG A5095 cohorts, 1012 and 1071 subjects had
advanced flow cytometry data and either documented urine dipstick protein or serum
creatinine, respectively. The characteristics of the study subjects included in the proteinuria
analyses are presented in Table 1. The characteristics of those included in the CrCl analyses
were nearly identical (data not shown).
In the combined cohort, the percentage of CD8+CD38+HLA-DR+ cells was significantly
higher in those with dipstick proteinuria ≥1+ compared to those without proteinuria in the
total cohort [55% (44, 69) vs. 50% (37, 61); P=0.01, Stratified Wilcoxon Rank Sun]. There
were significantly higher proportions of CD8+CD38+HLA-DR+ cells in those with
proteinuria compared to those without proteinuria in non-Hispanic Blacks [53% (43, 59) vs.
45% (34, 58)], Hispanics [70% (55, 78) vs. 57% (46, 67)], and men [55% (45, 70) vs. 49%
(37, 61)], regardless of race or ethnicity, in the combined cohort. The association between
proteinuria and higher proportions of CD8+CD38+HLA-DR+ cells in the total cohort
remained significant (P<0.01) after adjustment for study group (384 vs. A5095/ALLRT),
sex, race, and ethnicity.
The percentage of CD8+CD38+HLA-DR+ cells in those with CrCl <90mL/min was non-
significantly higher compared to those with higher CrCl in the overall combined cohort
[53% (38, 65) vs. 49% (37, 61); P=0.08, Stratified Wilcoxon Rank Sum]. Contrary to the
proteinuria analyses, there were no significant associations between higher immune
activation and reduced CrCl in subgroups based on race, ethnicity, or sex. There was also no
significant correlation between percentage immune activation and CrCl in the total cohort.
There was a notable and statistically significant difference in immune activation levels
between the two studies [49% (38, 60) in 384 vs. 53% (37, 64) in A5095/ALLRT; P=0.02].
We then focused on the individual study groups, so that the differences between the study
cohorts would not be missed. There was a higher percentage of CD8+CD38+HLA-DR+
cells in ACTG 384 study participants with proteinuria compared to those without proteinuria
[57% vs. 48%; P=0.005]. Characteristics of those with and without proteinuria in ACTG
384 are shown in Table 2. Variables associated with proteinuria or the percentage of
CD8+CD38+HLA-DR+ cells in univariable or bivariable analyses were included in the final
multivariable models (Table 3). Because of the strong correlation between CD4 cell count
and HIV-1 RNA level in ACTG 384, two models were constructed for this study group
incorporating each of these variables separately. In both 384 models, the percentage of
CD8+CD38+HLA-DR+ cells, lower hemoglobin levels, and being non-Hispanic Black
remained significantly associated with proteinuria. CD4 cell count was marginally
associated with proteinuria in Model 1, but HIV-1 RNA level was not associated with
proteinuria in Model 2.
Table 4 shows the univariable comparisons between those with and without CrCl <90mL/
min in ACTG 384. The percentage of CD8+CD38+HLA-DR+ cells was higher in those with
reduced CrCl compared to those without reduced renal function (53% vs. 48%; P=0.04).
Multivariable models assessing the relationship between reduced CrCl and immune
activation in ACTG 384 (Table 3) were constructed similarly to those for the proteinuria
analyses. However, as age, weight, and sex are already included in the Cockcroft-Gault
estimating formula, these variables and body mass index (which also uses weight for its
estimation) were not included in the models. Higher immune activation, non-Hispanic Black
race, and lower hemoglobin remained significantly associated with CrCl <90mL/min.
However, there was no significant correlation between CrCl modeled as a continuous
variable and immune activation in this study group.
Gupta et al. Page 3













In the A5095 study group, the percentages of activated CD8 cells were not significantly
different in those with and without dipstick proteinuria (Table 2). Using the same co-variates
as in the ACTG 384 analyses to assess multivariable predictors of proteinuria, we found that
higher HIV-1 RNA levels were significantly associated with proteinuria whereas being non-
Hispanic White appeared to be associated with not having proteinuria in A5095/ALLRT.
Unlike the ACTG 384 cohort, the percentage of CD8+CD38+HLA-DR+ cells, hemoglobin
level, non-Hispanic black race, and CrCl <90mL/min were not associated with proteinuria in
the A5095/ALLRT model.
There was also no difference in CD8 immune activation in those with and without reduced
renal function in A5095/ALLRT (Table 4). The multivariable predictors of CrCl <90mL/
min in A5095/ALLRT are shown in Table 3. Lower CD4 cell counts and smaller height
were associated with CrCl <90mL/min in this cohort. Like in the 384 study group, no
significant correlation was found between CrCl and immune activation in the A5095/
ALLRT study group.
Discussion
In this large cohort of antiretroviral-naïve, HIV-infected subjects about to initiate
antiretroviral therapy, we found that dipstick proteinuria, but not CrCl <90mL/min, was
significantly associated with a higher percentage of peripheral blood CD8+CD38+HLA-DR
+ cells. The absolute difference in median immune activation of 5% between those with and
without dipstick proteinuria in the combined cohort has been shown to be significantly
associated with poorer CD4 cell count increases after initiation of antiretroviral therapy [12].
There were even larger differences in immune activation in specific subgroups, including
non-Hispanic Blacks, Hispanics, and men. The prognostic implications of these findings will
require longitudinal analysis in additional studies.
The findings from the current study suggest that nephropathy, as reflected in dipstick
proteinuria, may be related to worse clinical outcomes due to increased systemic immune
activation. It is tempting to speculate that viral replication in the renal reservoir may lead to
increased local and systemic immune activation through persistent inflammatory stimulation
[7]. Conversely, higher systemic immune activation, whatever the underlying cause, may
somehow induce increased infiltration of activated T cells into the renal interstitium which
consequently causes renal damage.
We did not find that CrCl was significantly associated with higher systemic immune
activation in the overall cohort, although there did appear to be a significant association in
the 384 study group. However, the exclusion of those individuals with more advanced renal
dysfunction from these trials may have precluded our ability to detect a relationship between
lower CrCl and immune activation.
In light of the recent results from the Strategies for Management of Antiretroviral Therapies
(SMART) study [13], in which antiretroviral treatment interruption significantly increased
the risk of serious organ dysfunction, the results of the current study may have potential
relevance. It has been suggested that increased inflammation due to treatment interruption
may result in a greater risk for developing an elevated cystatin C level, another marker of
kidney dysfunction [14]. Our results demonstrate that increased systemic immune activation,
possibly a result or in conjunction with other inflammatory mediators, may be in the
pathway of events leading to renal failure in HIV-infected patients.
The findings presented here were plainly dependent on the study cohort. It is not clear why
there were such disparate results based on study cohort. We investigated multiple potentially
confounding variables (including region of enrollment, medical infectious/inflammatory
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diagnoses, degree of proteinuria; data not shown), but none explained the discrepancies in
results. Of course, there may have been unmeasured confounders that affected the results.
The results from the A5095 study group may have been affected by the non-random
selection of participants who co-enrolled in A5001 and had advanced flow cytometry results
available. We must also allow the possibility of chance playing a role in the discrepancies
found in our analyses.
Additional limitations include the cross-sectional observational design of this study, which
does not allow us to infer causality. Second, the inclusion criteria for the two trials included
in our investigation precluded enrollment of those with more severe renal dysfunction. In
addition, these results may be applicable only to those patients about to start cART. The
single measurement of immune activation and renal disease markers may have led to some
misclassification of subjects, especially those whose renal function estimates were near the
cutoff of 90mL/min used in these analyses. The use of renal function estimating equations,
including the Cockcroft-Gault formula, may not be reliably accurate in relatively normal
ranges [15]. Finally, other markers of inflammation (e.g. high sensitivity C-reactive protein,
interleukin-6) and quantitative measures of proteinuria and albuminuria may provide greater
and more precise insights into the associations between renal disease and immune activation.
To overcome these limitations, future studies investigating the relationships between
nephropathy and immune function should be longitudinal, include patients with more severe
renal dysfunction, and use several and quantitative measurements of proteinuria and kidney
function for more accurate categorization.
In summary, we found that dipstick proteinuria, but not estimated CrCl less than 90mL/min,
was associated with higher proportions of peripheral blood CD8+CD38+HLA-DR+ cells.
However, these findings were driven by the results from the ACTG 384 study group. As
such, these findings should be considered hypothesis-generating and should be confirmed in
larger prospective studies.
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Table 1
Characteristics of the study subjects in the proteinuria analyses.
Variable ACTG 384 N=576 ACTG A5095/ALLRT N=436 Total N=1012
Age, yrs 35 (30, 42) 37 (32, 43) 36 (31, 43)
Male n, (%) 472 (82) 375 (86) 846 (84)
Race/ethnicity, n (%)
 Black, non-Hispanic 219 (38) 126 (29) 346 (34)
 White, non-Hispanic 265 (46) 205 (47) 472 (47)
 Hispanic 81 (14) 96 (22) 176 (17)
CD4 cell count/μL
 Median 275 (100, 452) 244 (109, 374) 262 (103, 425)
 <200, n (%) 216 (38) 180 (41)
Log10 HIV-1 RNA/mL 4.95 (4.35, 5.54) 4.75 (4.38, 5.33) 4.85 (4.37, 5.47)
Hemoglobin, g/dL 13.7 (12.5, 14.9) 13.8 (12.5, 14.8) 13.7 (12.5, 14.8)
Hypertension, n (%) 36 (6) 36 (8) 72 (7)
Diabetes mellitus, n (%) 9 (2) 16 (4) 25 (2)
Viral hepatitis B or C co-infection, n (%) 38 (7) 68 (16) 106 (10)
Creatinine clearance, mL/min
 Median 113 (95, 138) 121 (99, 143) 116 (96, 141)
 <90, n (%) 104 (18) 72 (17) 176 (18)
Proteinuria, n (%)
 ≥1+ 39 (7) 34 (8) 73 (7)
 ≥2+ 17 (3) 7 (2) 24 (2)
 ≥3+ 6 (1) 1 (<1) 7 (<1)
%CD8+/CD38+/HLA-DR+ 49 (38, 60) 53 (37, 64) 50 (37, 62)
NOTE. All values are presented as median (25th percentile, 75th percentile) unless otherwise specified.
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